Printer Friendly

GENETICS INSTITUTE AND AMGEN SETTLE EPO DISPUTE

 CAMBRIDGE, Mass., May 11 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENIZ) and Amgen Inc. (NASDAQ: AMGN) announced today they have agreed to settle a long-standing patent dispute involving erythropoietin (EPO). The settlement between Genetics Institute and Amgen brings to a close all outstanding patent disputes on EPO in the United States between the two companies.
 As part of the settlement, Genetics Institute has agreed to pay Amgen $14.0 million. An additional $2.0 million may become payable contingent upon the outcome of certain future events. A portion of these payments will be reimbursed by Boehringer Mannheim GmbH, Genetics Institute's EPO licensee in Europe.
 "In March 1991, Genetics Institute recorded a charge of $11.0 million against earnings as a reserve for the ultimate resolution of potential damages payable to Amgen," said Garen Bohlin, executive vice president of Genetics Institute. "Because of this previously recorded reserve, the settlement payment to Amgen will not have a significant effect on this fiscal year's results of operations," he continued.
 "We are gratified that this agreement has been reached. It clears the way for the issuance of Amgen's previously allowed recombinant erythropoietin process and product patents in the United States," stated Gordon Binder, Amgen's chairman and chief executive officer.
 In August 1991, Amgen's licensee, Ortho Pharmaceutical Corporation (Ortho), initiated infringement proceedings against Genetics Institute in the U.S. District Court for the District of Massachusetts. Ortho moved to consolidate the case with the suit brought by Amgen. Upon motion by Genetics Institute and Amgen, Ortho's claims were dismissed and Ortho has appealed the District Court's decision. A decision on the Ortho appeal is pending.
 Amgen Inc. is a global biotechnology company that develops, manufactures and markets human therapeutics based on advanced cellular and molecular biology.
 Genetics Institute is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of licensed and proprietary products at various stages of development, including treatments for anemia, hemophilia, cancer, bone damage, heart disease, inflammatory conditions, and immune system disorders.
 American Home Products Corporation (NYSE: AHP) holds a majority interest in Genetics Institute. AHP is a world leader in the marketing and manufacturing of prescription drugs, medical supplies, diagnostics, over-the-counter medicines and food products.
 -0- 5/11/93
 /CONTACT: Dennis Harp or Gina Brazier, Genetics Institute, Inc., 617-876-1170; Sarah Crampton (investor relations), 805-447-1659 or Kimberly Dorsey (media), 805-447-4367, both of Amgen Inc./
 (GENIZ, AMGN)


CO: Genetics Institute, Inc.; Amgen Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE016 -- 7061 05/11/93 12:26 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993
Words:428
Previous Article:3M SHAREHOLDERS ELECT SIX DIRECTORS
Next Article:ATLANTIC RESTAURANT VENTURES, INC. REPORTS THIRD CONSECUTIVE QUARTER OF INCREASED EARNINGS
Topics:


Related Articles
JOHNSON & JOHNSON ANNOUNCES AMGEN ARBITRATION DISPUTE
GENETICS INSTITUTE TO APPEAL EPO DECISION FAVORING AMGEN
Hoechst Marion Roussel and Transkaryotic Therapies Seek Dismissal of Amgen Patent Suit
Arbitrator Orders Amgen to Pay Ortho Biotech Approximately $205 Million

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters